Ming Shen

Ming Shen is an accomplished professional with extensive experience in regulatory affairs and chemistry. Currently serving as the Executive Director of CMC Regulatory Affairs at Sarepta Therapeutics since September 2019, Ming leads the RA CMC team for RNA Technologies, overseeing strategy and support for over 10 programs from early clinical development to post-approval. Previous roles include Director of CMC Regulatory Affairs at TESARO, Associate Director of Regulatory CMC at Takeda Pharmaceuticals, and various positions at Millennium Pharmaceuticals and Boehringer Ingelheim, demonstrating a strong background in regulatory support, process chemistry, and drug development. Ming holds a Doctor of Philosophy (Ph.D.) in Organic Chemistry from the University of Toronto.